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project brief

PROGESTERONE VAGINAL RING
BENEFICIAL ROLE IN BIRTH SPACING
The Progesterone Vaginal Ring (PVR)
is a vaginal ring which contains
progesterone and can enhance the
effect of breastfeeding on birth spacing.
CONTRACEPTIVE EFFECT OF
EXCLUSIVE BREASTFEEDING
Postpartum family planning has received renewed focus with
the issuance of new guidelines from the World Health
Organization; some estimates of unmet need for
contraception among women during the postpartum period
are more than 60% in developing countries1,2.
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In this context, the lactational amenorrhea method (LAM) is
recognized as an effective means of postponing the return to
fertility in breastfeeding mothers as indicated by the onset of
menstrual bleeding3-9. LAM is defined as a method that can
effectively protect a woman from pregnancy if she meets all
of the following three criteria: 1) Her period has not returned
since her baby was born; 2) She is breastfeeding exclusively
(fully) day and night, i.e. breast milk is the only source of
water or nutrients during the first six months as long as the
infant’s growth is adequate; 3) Her baby is less than six
months old. As soon as the woman no longer meets one of
these criteria, pregnancy rates increase and she needs to
begin using another contraceptive method.
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Based on recent DHS surveys, however, a low proportion of
women report compliance with the three criteria for the use
of LAM in DHS surveys (usually less than 5% of breastfeeding
women)10, although results from a large multicenter study on
efficacy of LAM conducted in the early 1990s, suggest that
deviation from specific use of each of the three criteria does
not cause a significant upsurge in pregnancy rates11. It has
been shown that the PVR as a new method of contraception
during lactation, can provide additional protection to
breastfeeding women who want to space their pregnancies
for more than one year, but may not comply with the strict
criteria of LAM.
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Lactational amenorrhea and its associated
infertility have been shown to contribute to birth
spacing, although variable effectiveness has
been reported among different communities. In a
population of highly motivated Chilean women
(n=236) who breastfed up to 8 times per day, the
risk of experiencing the first bleeding was
reduced while fully breastfeeding with a high
number of nursing episodes per day and night,
but 25% and 50% of the women had started to
cycle by the end of the fifth and eight postpartum
month respectively3.
After the first postpartum menses, the risk of
pregnancy for breastfeeding women increases
substantially3,12. The cumulative probability of
pregnancy changes from 0.9% in amenorrheic
women to 36% in cycling women at 6 months

postpartum; and at 12 months, the pregnancy rate
increases further from 17% (in amenorrheic women) to
55% (in cycling women)12.
Diaz et al4 demonstrated that the onset of bleeding before
the sixth postpartum month, in fully breastfeeding women,
predicts a higher risk of pregnancy. The investigators
calculated the probability of experiencing the first
bleeding and the probability of pregnancy in 236 women
who were fully breastfeeding and not using contraception
and enrolled during the first month postpartum4-11. The
cumulative probability of bleeding and of pregnancy was
52% and 9.4% at day 180 postpartum, respectively. The
risk of pregnancy was less than 2% in the subset of
amenorrheic women4. These results confirmed that
lactational amenorrhea provides effective contraceptive
protection during the first six months postpartum. They
also suggested that the first postpartum bleeding marks a
discernible increase in the risk of pregnancy 4,12.
After the sixth month postpartum, when breastfeeding will
probably cease to be “full” or nearly full, it is increasingly
likely that ovulation will precede the first vaginal bleed.
Therefore, the protection against pregnancy that is
afforded by breastfeeding decreases over time to levels
lower than those of other family planning methods5.
Based on these data, participants in a Bellagio consensus
conference5 concluded that the maximum birth spacing
effect of breastfeeding is achieved when a mother ‘fully”
or nearly fully breastfeeds and remains amenorrheic.
When these two conditions are fulfilled, breastfeeding
provides more than 98% protection from pregnancy in the
first six months5.

CONTRACEPTIVE METHODS IN
BREASTFEEDING WOMEN
As a result of the growing urbanization and changing
social norms about the role of women in developing
countries, the duration of exclusive breastfeeding and its
impact as a contraceptive strategy has been reduced. This
situation has given rise to the need for a contraceptive
method that could extend the infertile period following
delivery, especially in countries where access to other
contraceptives is limited and where longer duration of
breastfeeding is a social norm and a major benefit to
infant health.
According to WHO Medical Eligibility Criteria (MEC),
several methods are suitable for women who are
breastfeeding and can be recommended13. Progestin-only
pills (POP) have a longer half-life than progesterone, but
need to be taken daily at approximately the same time.
Long-acting methods such as the progestin implant or an
intrauterine device (IUD) require access to trained health
care providers for insertion and removal. The PVR was
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developed as a new user-controlled method that delivers
a natural hormone for 3 consecutive months, hence not
requiring daily attention by the user. Progesterone is
metabolized quickly after ingestion in breast milk, limiting
the steroid exposure to the infant.

MECHANISM OF ACTION OF THE PVR
The contraceptive mechanism of action of natural
progesterone is similar to that of progestin-only pills, i.e. it
suppresses ovulation, and reinforces the prolactin
response to suckling9.
Diaz et al9 explored the mechanism of action of progesterone rings in lactating women by comparing ovarian function
and prolactin levels between women who chose either a
PVR or a Copper IUD at day 60 postpartum. Data were
provided based on monthly follow up during one year of
use. Frequency of breastfeeding and pregnancy rates in
women who were relying only on lactational infertility were
collected separately for comparative purposes9,12.
The women (defined as fully or exclusively breast-feeding)
were instructed not to give their babies any liquid or solid
food or water during the first 6 months postpartum and to
use the breast as the only source of fluids and nutrients,
with the exception of vitamin drops. Milk supplements
were indicated only when inadequate infant growth was
diagnosed. Non-dairy meals were introduced after the
sixth postpartum month.
The endocrine profile during the first 8 months postpartum was assessed in a sub-group of breastfeeding
women including 36 PVR-treated women and 28 IUDusers. Pre- and post-suckling prolactin (PRL) levels were
measured at fortnightly intervals and E2 determinations
and ovarian ultrasound were performed twice a week.
Post-suckling PRL levels were significantly higher among
PVR users (n=20) compared with IUD users (n=12);
p=0.009. In PVR users, progesterone plasma levels
ranged from 10 to 20 nmol/L, at lower levels than in a
normal luteal phase. Similarly, E2 levels were lower, and
follicular growth was arrested at earlier stages in the PVR
vs. the IUD groups (Figures 1 & 2).

FIGURE 1 ESTRADIOL SERUM LEVELS BY
MONTH OF EXPOSURE

Mean of the Highest E2 Level in Lactating Women Treated with a Progesterone
Vaginal Ring (PVR) or a Copper-T Device (IUD) p < 0.05 except in month 6 (M6).
(Adapted from Diaz et al9)

FIGURE 2 FOLLICLE DIAMETER AMONG USERS
OF PVR OR IUD (3–8 MOS. POSTPARTUM)

The authors concluded that progesterone increases the
sensitivity of the breast-hypothalamic-pituitary system to
suckling, as shown by the higher PRL levels in women using
the PVR, and reinforces the mechanism of lactational
infertility9. They also concluded that progesterone may
affect the GnRH-releasing process independently of
suckling9. These results, therefore, support the efficacy of
the PVR in suppressing ovulation for a longer duration as
compared with “untreated” women who demonstrate
resumption of follicle growth and possible ovulation even
when fully breastfeeding.

CONTRACEPTIVE EFFICACY OF THE PVR
In the study by Diaz et al9, pregnancy rates at the end of the
year were 0.6% in PVR users and 0.7% in IUD users. In
another study that included the population of 236
breastfeeding only women, the pregnancy rates at one year
were 39%12 (Table 1).

TABLE 1 CONTRACEPTIVE EFFICACY OF THE
PVR IN NURSING WOMEN
Women
Pregnancies/WMb
Pearl Index
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PVR
Users
246a
1/2016
0.6

T-CU Users
442
2/3461
0.7

Untreated
Womenc
226
50/1552
38.7

Adapted from Diaz et al 9.
aPVR 5 mg (n = 76), 10 mg (n = 109), or 15 mg (n = 61). bWM= womanmonth; PVR and T-Cu were administered at day 60 ± 5 postpartum and the
women were followed until month 14 postpartum. Untreated women were
followed until month 12 postpartum. cThe untreated group has been collected
in another study12 and used in this table as historical comparison.

All women in the PVR and IUD groups were amenorrheic
at admission. By the end of month 8 postpartum, 78%
of PVR users and 29% of T-Cu users remained so. The
PVR group experienced a significantly lower risk of
bleeding (p <0.0001) than did the IUD group.
Massai et al14 also studied the contraceptive efficacy
and safety of the PVR compared to the Copper T 380A
IUD (T-Cu) in breastfeeding women enrolled at three
Chilean clinics. A total of 285 volunteers chose to use
the PVR and 262 women used the T-Cu. Ring replacement was scheduled every 3 months. Volunteers continued in the study until weaning or completing the continuous use of four PVRs over one year. No pregnancies
occurred in 2,320 and 2,183 woman-months of
exposure with the PVR and the T-Cu, respectively.
The mean duration of lactational amenorrhea was 361
± 9 days in the PVR group and 198 ± 8 days in the T-Cu
group (p<0.0001). The proportion of amenorrheic
women at the 6th month postpartum was 87.4% among
PVR users and 41.5% among T-Cu users (p = 0.0001).
These percentages were three- and six fold higher in the
PVR than in the T-Cu groups at months 9 and 12,
respectively14. The mean number of breastfeeding
episodes was similar in both groups, decreasing from a
mean of 10.1 episodes/day at month 3 to a mean of 5
episodes/day at month 14 postpartum. Infant weights
were similar in both groups14.
In the Population Council’s large comparative
multicentric trial that compared 802 women using the
PVR and 734 women who received a copper-T 380A
IUD, the 1-year pregnancy rate with the ring was at 1.5
per 100 (431 women-years) and 0.5 per 100 in the
copper-T 380A cohort (533 women-years). The
percentage of women who were amenorrheic at 6
months postpartum was 67.4% in the PVR group and
43.7% among IUD users (p=0.0001); and at month 12,
the rate of amenorrhea remained higher in the PVR
group at 46.2% vs 16.1% in the IUD group (p=0.0001).
There was no difference between groups in the mean
number of breastfeeding episodes per day (d) which
was around 9 meals/day at initiation and 6meals/d at
12 months15. In addition, the weight of the infants did
not differ between PVR or IUD users except at 12
months and attributed to more supplements given in
the IUD group15.

Preliminary results from a recent study of PVR vs.
IUD use conducted in India (2012-2015) provides
similar results with respect to rates of lactational
amenorrhea and average daily breastfeeding
episodes over time. Pregnancy rates were identical
(1 pregnancy in each group) as were infant growth
patterns (ICMR & Population Council Internal Data –
Protocol 418).

SUMMARY
Results of clinical trials completed to date support the
following conclusions regarding the role of breast-feeding
and use of the PVR to promote child spacing:
• Breastfeeding protects against pregnancy if a woman is
fully breastfeeding and remains in amenorrhea; in this
case her pregnancy risk will be about 0.9% at 6 months
postpartum12.
• When a first bleeding occurs before the 6th month, the
risk of pregnancy increases to 9% and higher5,12.
• The risk of experiencing the first bleeding is reduced while
fully breastfeeding with a high number of nursing episodes
per day and night, but nevertheless 25% and 50% of the
women start to cycle by the end of the fifth and eight
postpartum month, respectively3.
• Using a Progesterone Vaginal Ring (PVR) prolongs
amenorrhea in a higher proportion of women compared to
women who are breastfeeding only. At 6 months, 87.4% of
PVR users are amenorrheic versus 41.5% in IUD users14.
• Users of a PVR show a higher suppression of ovarian
follicles as compared with women using an IUD, with a
majority of follicles at a diameter <10mm (82%), while IUD
users show only 54% of follicles at <10mm. Follicles of
>15mm were seen in 4% of PVR users and 23% of IUD
users9.
• In fully breastfeeding women, pregnancy rates at the end
of one year are observed at < 1% in PVR users (treated)
and at 39% in breastfeeding women not using any other
contraception9,12. This low failure rate of the PVR appears
to have been replicated in a recent study in India.
Based on the review of the literature herein discussed, as
well as preliminary findings from the recent study in India, it
may be concluded that the PVR is effective in preventing an
early return of follicle growth and ovulation, and preventing
the return of cycling and fertility that may occur even in
women who are fully breastfeeding9,12. A recent review of
unmet need among postpartum women also suggests that in
contexts where breastfeeding is common, counseling women
about LAM and urging contraceptive adoption within six
months of birth has programmatic rationale16.
These conclusions support the position of offering the PVR to
women who plan to breastfeed in the context of postpartum
contraceptive counseling. In this regard, WHO has issued the
following recommendation for use of the PVR:

“Women who breastfeed and are four or more weeks
postpartum can use the PVR without restrictions
(MEC category 1)”.
The Guideline Development Group advised that women who
use the PVR must be actively breastfeeding (e.g. at least four
breastfeeding episodes per day) to maintain the efficacy of

the method13.
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